Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: tocilizumab

Two Inflammatory Conditions—Polymyalgia Rheumatica and Giant Cell Arteritis—Share Clinical Connection

William P. Docken MD  |  March 1, 2013

Polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) have common clinical and epidemiologic links, but they need not occur synchronously

Filed under:ConditionsSoft Tissue Pain Tagged with:Clinicalinflammationrheumatology

Rheumatology Drug Updates

Michele B. Kaufman, PharmD, BCGP  |  January 1, 2013

Information on new approvals and medication safety rheumatologists need to know

Filed under:Drug Updates Tagged with:adalimumabDrugsFDAguidelineSafety

EULAR 2012: Remission the New Normal for Rheumatoid Arthritis

Thomas R. Collins  |  August 8, 2012

Advances in the rheumatology clinic are promising, two experts say.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesEULAR/OtherMeeting ReportsRheumatoid Arthritis Tagged with:BiologicsEULARHYDROXYCHLOROQUINEinfliximabInternationalMethotrexatepatient careRheumatoid arthritisrheumatologisttocilizumab

Cardiovascular Disease in Rheumatoid Arthritis

Katherine P. Liao, MD, MPH  |  July 10, 2012

How to improve management of heart disease in patients with RA.

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:cardiovascularCardiovascular diseasepatient careResearchRheumatoid arthritisrheumatologist

Drug Updates

Michele B. Kaufman, PharmD, BCGP  |  July 9, 2012

Information on new approvals and medication safety.

Filed under:AnalgesicsAxial SpondyloarthritisBiologics/DMARDsConditionsDrug UpdatesRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:Ankylosing SpondylitisBiologicsbiophosphonatesdrugJAK inhibitorsjanus kinaseMethotrexateopioidPainRheumatoid arthritisrheumatologistrituximabSafetySystemic lupus erythematosustocilizumabTofacitinib

ACR Issues Guidelines, Recommendations for Lupus Nephritis, RA

Kathy Holliman  |  June 10, 2012

Detailed screening and treatment recommendations based on current evidence, extensive literature review.

Filed under:Biologics/DMARDsClinical Criteria/GuidelinesConditionsDrug UpdatesFrom the CollegeRheumatoid ArthritisSystemic Lupus Erythematosus Tagged with:AC&RAmerican College of Rheumatology (ACR)BiologicsdrugGlucocorticoidsGuidelinesLupusLupus nephritispatient careRheumatoid arthritisSystemic lupus erythematosustocilizumab

Systemic Juvenile Idiopathic Arthritis

Rayfel Schneider, MBBCh, and Ronald M. Laxer, MDCM  |  May 9, 2012

Changing treatment paradigms in the biologic era

Filed under:Clinical Criteria/GuidelinesConditionsRheumatoid Arthritis Tagged with:AC&RAmerican College of Rheumatology (ACR)anti-inflammatorydrugJIAJuvenile idiopathic arthritismacrophage activation syndromeMethotrexatepatient carePediatricsrheumatologistSteroidstocilizumabTreatment

Information on New Drug Approvals and Medication Safety

Michele B. Kaufman, PharmD, BCGP  |  March 8, 2012

Rheumatology-related drug safety, approvals, and what’s in the pipeline.

Filed under:Biologics/DMARDsConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:anti-inflammatoryBiologicscrystal arthritisdrugGoutJAK inhibitorsjanus kinaseMethotrexateRheumatoid arthritisrheumatologistSafetyTofacitinib

Drug Updates

Michele B. Kaufman, PharmD, BCGP  |  November 1, 2011

Information on new approvals and medication safety

Filed under:Drug Updates Tagged with:anti-inflammatoryApprovalsAutoimmuneDrugsFDAPipelineSafetytumor necrosis factor

A Meeting of the Minds for RA Research

Thomas R. Collins  |  August 1, 2011

REF investigators gather to share research progress and trade advice

Filed under:ConditionsResearch RheumRheumatoid Arthritis Tagged with:ACR Research and Education Foundationlung diseaseResearchRheumatoid arthritisWithin Our Reach

  • « Previous Page
  • 1
  • …
  • 26
  • 27
  • 28
  • 29
  • 30
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences